Pharmaceuticals business now has a Marketing Minded Pres to Pitch
Steve’s breakdown: We love it when marketing professionals take control of a substantially large ad account. This time it’s Bayer and Sebastian Guth and we believe, giving the present roster of ad agencies on their roster, there are probably going to be some upgrades.
WHIPPANY, NJ: Bayer today announced the appointment of Sebastian Guth as President of Pharmaceuticals, Americas Region, comprising the United States, Canada, Central and Latin America, effective December 1, 2018.
“Sebastian is a highly respected, seasoned leader in the pharmaceutical industry, and I’m thrilled to have him lead Bayer’s largest pharmaceutical business worldwide,” said Dieter Weinand, member of Bayer’s Board of Management and President of Pharmaceuticals. “Sebastian brings significant global experience gained from leadership roles in strategy, marketing, and business development and a proven track record of successful execution at the local level that will be crucial as we continue our growth in the U.S. and across the Americas region.”
A member of Bayer’s Pharmaceutical Executive Committee, Guth has since October 2015 served as Executive Vice President and Chief Marketing Officer for Bayer’s global Pharmaceuticals business. Previously, he served as Chief Marketing Officer for Bayer’s global General Medicine business. Prior to that, he was President & Chief Executive Officer of Bayer Yakuhin Ltd., Osaka, leading Bayer’s healthcare business in Japan.
Guth started his career in the pharmaceuticals industry with Schering AG, where he held senior roles in Asia and the Middle East. Guth was later appointed Head of Strategy and Business Development for Schering’s European business. Following Bayer’s acquisition of Schering in 2006, he acted as Chief Executive Officer of Bayer Turk, Istanbul, and was Senior Representative of the Bayer Group in Turkey.
Guth succeeds Carsten Brunn and will be based in Whippany, New Jersey.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.us.